4 de agosto de 2015

Recursos de MBE del American Family Physician

http://www.aafp.org/journals/afp/authors/ebm-toolkit/resources.html

Cómo realizar una espirometría de calidad

https://www.youtube.com/watch?v=6KIPK92OYnE&index=15&list=PLX8gn9E0dsu5j3Jb_rg4nUDOEeUHi2oTF

Un video de P2P FEGAS

"P2P: del Profesional para el Profesional" es un programa formativo de la Fundación Pública Escuela Gallega de Administración Sanitaria (FEGAS) basado en la gestión del conocimiento a través de píldoras formativas que responden a necesidades formativas básicas en el ámbito clínico con contenidos breves y directos. 

¿QUÉ ES LA ASMATECA?

http://www.separasma.com/que-es-la-asmateca/


Ejercicio aeróbico y asma

Aerobic training decreases bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: a randomised controlled trial


Conclusions Aerobic training reduced bronchial hyperresponsiveness  and serum proinflammatory cytokines and improved quality of life and asthma exacerbation in patients with moderate or severe asthma. These results suggest that adding exercise as an adjunct therapy to pharmacological treatment could improve the main features of asthma.

Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

http://www.ncbi.nlm.nih.gov/m/pubmed/26208998/?i=5&from=copd

(COCHRANE): En un paciente con asma bien controlado con LABA + Corticoides inhalados ¿se debe suspender el LABA?


(COCHRANE) En un paciente con asma bien controlado con LABA + Corticoide inhalado ¿se debe suspender el LABA?

Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011306.pub2/abstract

Authors' conclusions

This review suggests that stopping LABA in adults who have stable asthma while they are taking a combination of LABA and ICS inhalers may increase the likelihood of asthma exacerbations that require treatment with oral corticosteroids, but this is not certain. Stopping LABA may slightly reduce asthma control and quality of life, but evidence was insufficient to show whether this had an effect on important outcomes such as serious adverse events and exacerbations requiring hospital admission, and longer trials are warranted. Trialists should include patient-important outcomes such as asthma control and quality of life and should use validated measurement tools. Definitions of exacerbations should be provided.

Olodaterol. Informe del CADIME

http://www.cadime.es/es/fnt.cfm?fid=110

Sensitivity of different spirometric tests for detecting airway obstruction in childhood asthma

http://informahealthcare.com/doi/abs/10.3109/02770903.2014.984842


Conclusions: 
(1) Tests at low lung volumes (small airway tests) are more sensitive than large airway tests; 
(2) Within groups, the FEV1 is better than PEFR and FEF75 is better than FEF25–75 or FEF50.


REVIEW - Diagnosis And Monitoring Of Chronic Obstructive Pulmonary Disease

http://www.hsric.nihr.ac.uk/topics/review-diagnosis-and-monitoring-of-chronic-obstructive-pulmonary-disease/

Horizon Scanning Research & Intelligence Centre

What does the future hold for COPD diagnostic and monitoring technologies?



Chronic obstructive pulmonary disease (COPD) is a lifelong, progressive and incurable disease of the airways that affects more than 1.5 million people in England and Wales. Patients experience shortness of breath and cough, which restricts their daily life, and many also suffer periods when their symptoms get rapidly worse. These ‘exacerbations’ are often due to infection and usually require treatment with antibiotics and corticosteroids, often in hospital. COPD is therefore a significant burden on patients, carers and the NHS.

Currently, the diagnosis of COPD is often delayed, meaning that patients miss out on appropriate care in the early stages of their disease. In addition, COPD exacerbations are usually treated without knowing the specific cause of the exacerbation, which exposes some patients to unnecessary treatments, a particular concern given the increasing development of antibiotic resistance and the potentially significant side effects of corticosteroids. In this review, we sought to determine whether any technologies currently in development could address these issues. We identified technologies by searching a wide range of online sources, and then asked clinical experts and patients with COPD to comment on each technology’s level of innovation, likely impact on patients and health services, acceptability to users, and likelihood of adoption by the NHS.